West Pharmaceutical Services Inc (WST)
390.07
-0.13
(-0.03%)
USD |
NYSE |
Apr 24, 13:50
West Pharmaceutical Services Enterprise Value: 27.92B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 23, 2024 | 27.92B |
April 22, 2024 | 26.83B |
April 19, 2024 | 26.59B |
April 18, 2024 | 26.98B |
April 17, 2024 | 26.98B |
April 16, 2024 | 27.13B |
April 15, 2024 | 27.08B |
April 12, 2024 | 27.17B |
April 11, 2024 | 27.73B |
April 10, 2024 | 27.89B |
April 09, 2024 | 28.08B |
April 08, 2024 | 28.09B |
April 05, 2024 | 28.20B |
April 04, 2024 | 27.62B |
April 03, 2024 | 27.69B |
April 02, 2024 | 27.75B |
April 01, 2024 | 28.34B |
March 28, 2024 | 28.32B |
March 27, 2024 | 28.20B |
March 26, 2024 | 27.77B |
March 25, 2024 | 27.79B |
March 22, 2024 | 28.19B |
March 21, 2024 | 28.33B |
March 20, 2024 | 28.20B |
March 19, 2024 | 28.32B |
Date | Value |
---|---|
March 18, 2024 | 28.32B |
March 15, 2024 | 27.73B |
March 14, 2024 | 28.59B |
March 13, 2024 | 27.59B |
March 12, 2024 | 27.02B |
March 11, 2024 | 25.53B |
March 08, 2024 | 25.63B |
March 07, 2024 | 25.86B |
March 06, 2024 | 25.29B |
March 05, 2024 | 25.12B |
March 04, 2024 | 25.62B |
March 01, 2024 | 25.61B |
February 29, 2024 | 25.59B |
February 28, 2024 | 25.51B |
February 27, 2024 | 25.62B |
February 26, 2024 | 25.98B |
February 23, 2024 | 26.29B |
February 22, 2024 | 25.73B |
February 21, 2024 | 25.46B |
February 20, 2024 | 25.02B |
February 16, 2024 | 25.89B |
February 15, 2024 | 25.06B |
February 14, 2024 | 29.27B |
February 13, 2024 | 28.57B |
February 12, 2024 | 29.16B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.351B
Minimum
May 31 2019
34.48B
Maximum
Dec 30 2021
21.23B
Average
21.86B
Median
Aug 29 2022
Enterprise Value Benchmarks
Becton Dickinson & Co | 82.64B |
Abbott Laboratories | 194.31B |
Masimo Corp | 7.989B |
Merit Medical Systems Inc | 4.534B |
Insulet Corp | 12.41B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 137.00M |
Revenue (Quarterly) | 732.00M |
Total Expenses (Quarterly) | 562.20M |
EPS Diluted (Quarterly) | 1.83 |
Gross Profit Margin (Quarterly) | 38.01% |
Profit Margin (Quarterly) | 18.72% |
Earnings Yield | 2.02% |
Operating Earnings Yield | 2.41% |
Normalized Earnings Yield | 2.108 |